Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has earned a consensus rating of “Buy” from the twenty-three research firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, nine have issued a hold recommendation, twelve have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $82.03.

ALNY has been the topic of a number of recent analyst reports. Chardan Capital set a $95.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, May 5th. Vetr downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price on the stock. in a research report on Monday, May 15th. Piper Jaffray Companies set a $118.00 target price on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, May 15th. Ladenburg Thalmann Financial Services set a $80.00 price target on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, May 17th. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $102.00 price target on shares of Alnylam Pharmaceuticals in a research note on Thursday, June 22nd.

Shares of Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 81.44 on Friday. The stock’s market cap is $7.02 billion. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $86.92. The firm has a 50-day moving average price of $81.11 and a 200 day moving average price of $60.45.

In related news, SVP Akshay Vaishnaw sold 43,750 shares of the firm’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $65.00, for a total value of $2,843,750.00. Following the transaction, the senior vice president now owns 43,047 shares of the company’s stock, valued at approximately $2,798,055. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Sanofi purchased 297,501 shares of the company’s stock in a transaction that occurred on Wednesday, May 31st. The stock was acquired at an average cost of $71.87 per share, for a total transaction of $21,381,396.87. The disclosure for this purchase can be found here. In the last ninety days, insiders sold 64,125 shares of company stock worth $4,325,000. 4.30% of the stock is owned by insiders.

Several institutional investors have recently bought and sold shares of ALNY. First Manhattan Co. purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $135,000. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $148,000. Westpac Banking Corp purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $202,000. Prudential Financial Inc. purchased a new position in Alnylam Pharmaceuticals during the first quarter valued at approximately $215,000. Finally, CIBC Asset Management Inc purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $221,000. 88.96% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/09/alnylam-pharmaceuticals-inc-alny-receives-average-recommendation-of-buy-from-analysts-updated-updated-updated.html.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.